Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies
AffaMed, EverInsight will focus on ophthalmology, neurology and psychiatry drugs
Two newly merged companies backed by CBC are already looking ahead to an IPO, a week after a high-profile debut by another of the Asian investment firm’s portfolio companies.
The combination of AffaMed Therapeutics (Shanghai) Co. Ltd. and EverInsight Therapeutics, both of which launched last year, brings together programs in ophthalmology, neurology and psychiatry for the Chinese market as well as rights to an array of biosimilars. ...